ITEMS IN AFP WITH KEYWORD:
With Lembke article and opioid PG
Adopting high-value prescribing strategies can help family physicians increase the quality of care, decrease costs, and fulfill our professional obligation to provide health care that is based on the wise and cost-effective management of limited clinical resources.
Dec 1, 2015 Issue
Chlorthalidone vs. Hydrochlorothiazide for Treatment of Hypertension [FPIN's Help Desk Answers]
Chlorthalidone produces slightly greater reductions in blood pressure compared with hydrochlorothiazide (HCTZ), but it is associated with greater declines in serum potassium levels. Chlorthalidone lowers the risk of cardiovascular events about 18% more than HCTZ at the same achieved blood pressure.
Nov 1, 2015 Issue
Effectiveness of Selective Serotonin Reuptake Inhibitors for Irritable Bowel Syndrome [Medicine by the Numbers]
Studies show that 1 in 4 had improved bloating and stool consistency, and less interference with daily life, while only 1 in 9 experiences medication related adverse effects. Want to know more?
Family physicians should not naively accept a new technology because it is the latest trend. We need to assess the clinical utility of potential applications of genetic information, adopting them when they improve patient-oriented outcomes and avoiding them when they simply add costs for little to no benefit.
Clinical pharmacogenetics, the use of genetic data to guide drug therapy decisions, is increasingly being used for medications commonly prescribed by family physicians. Two common gene-drug pairs are discussed to illustrate how pharmacogenetic data can be applied clinically.
Pregnant women commonly ask their physicians about taking over-the-counter medications. Find out which medications are most likely safe, and which should be avoided if possible.
Prolonging dual antiplatelet therapy with aspirin plus clopidogrel (Plavix) for more than one year after the placement of a drug-eluting stent confers no clinical benefit.
In patients with diabetes, ACE inhibitors decrease cardiovascular events and all-cause mortality. ARBs do not. Both drug classes decrease heart failure incidence. Although both drug classes have been available for almost 15 years, there is only one study of 250 patients that directly compared their ...
The new guideline from the ACC/AHA increases the number of adults between 40 and 75 years of age who are eligible to take statins by 12.8 million. The largest increases were among adults who would take statins for primary prevention and for adults between 60 and 75 years of age. The authors estimate...